News headlines about ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ESSA Pharma earned a media sentiment score of -0.01 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.1195749423522 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
EPIX has been the topic of a number of analyst reports. Zacks Investment Research upgraded ESSA Pharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 18th. Dawson James reiterated a “buy” rating on shares of ESSA Pharma in a report on Thursday, August 3rd. Finally, Bloom Burton cut ESSA Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $4.75.
ESSA Pharma (NASDAQ EPIX) traded down 3.33% during midday trading on Wednesday, hitting $0.29. The stock had a trading volume of 100,706 shares. The stock’s market cap is $8.44 million. ESSA Pharma has a one year low of $0.25 and a one year high of $3.59. The firm has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.29.
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
What are top analysts saying about ESSA Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ESSA Pharma Inc. and related companies.